Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × 64Cu-SARTATE × 1 year × Clear all
NCT04023331 2025-09-16

67Cu-SARTATEâ„¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Clarity Pharmaceuticals Ltd

Phase 1/2 Terminated
21 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡